Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Authors
He, A. R.Valle, Juan W
Lee, C. K.
Ikeda, M.
Potemski, P.
Morizane, C.
Cundom, J. E.
Tougeron, D.
Dayyani, F.
Rokutanda, N.
Xiong, J.
Cohen, G.
Oh, D. Y.
Affiliation
Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC,Issue Date
2022
Metadata
Show full item recordCitation
He AR, Valle JW, Lee CK, Ikeda M, Potemski P, Morizane C, et al. Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study. Annals of Oncology. 2022 Nov;38(9):S1467-S8. PubMed PMID: WOS:000897943700088.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.10.122Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.10.122Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.10.122